Kaposi sarcoma is a neoplasm caused by human herpesvirus 8 (HHV8) that most commonly affects immunosuppressed patients. The skin is the most affected area, but other sites can be involved such as the lung, digestive tract and lymph nodes. The classical presentation involves a violaceous skin lesion that can be small or hidden, leading to a delay in diagnosis. We report a clinical case of a kidney transplant patient, who presented, 14 months after kidney transplant, with unilateral edema of the inferior member and cutaneous rash misdiagnosed and taken initially for erysipelas. The diagnosis of Kaposi’s sarcoma was retained, on a lymph node biopsy of an inguinal adenopathy. The evolution was marked by a local and general improvement after systemic chemotherapy, reducing Tacrolimus and discontinuation of Mycophenolate mofetil. Graft function remained stable during the follow-up.
References
[1]
Maluccio, M., Sharma, V., Lagman, M., Vyas, S., Yang, H., Li, B., et al. (2003) Tacrolimus Enhances Transforming Growth factor-β1 Expression and Promotes Tumor Progression. Transplantation, 76, 597-602. https://doi.org/10.1097/01.TP.0000081399.75231.3B
[2]
Lebbé, C., Legendre, C. and Frances, C. (2008) Kaposi Sarcoma in Transplantation. Transplant Reviews, 22, 252-261. https://doi.org/10.1016/j.trre.2008.05.004
[3]
Wendling, J., Francès, C., Thervet, E., Agbalika, F., Morinet, F. Bedrossian, J., et al. (2001) Maladie de Kaposi post-transplantation rénale. Le Courrier de la Transplantation, 1, 78-81.
[4]
Regamey, N., Tamm, M., Wernli, M., Witschi, A., Thiel, G., Cathomas, G., et al. (1998) Transmission of Human Herpesvirus 8 Infection from Renal-Transplant Donors to Recipients. The New England Journal of Medicine, 339, 1358-1363. https://doi.org/10.1056/NEJM199811053391903
[5]
Mourad, G., Serre, J.-E., Alméras, C., Basel, O., Garrigue, V., Pernin, V., et al. (2016) Complications infectieuses et néoplasiques après transplantation rénale. Néphrologie & Thérapeutique, 12, 468-487. https://doi.org/10.1016/j.nephro.2016.06.003
[6]
Sarid, R., Olsen, S.J. and Moore. P.S. (1999) Kaposi’s Sarcoma Associated Herpesvirus: Epidemiology, Virology, and Molecular Biology. Advances in Virus Research, 52: 139-232. https://doi.org/10.1016/S0065-3527(08)60299-7
[7]
Lebbé, C., Euvrard, S., Barrou, B., Pouteil-Noble, C., Garnier, J.L. and Glotz, D. (2006) Sirolimus Conversion for Patients with Post Tranplant Kaposi’s Sarcoma. American Journal of Transplantation, 6, 2164-2168. https://doi.org/10.1111/j.1600-6143.2006.01412.x
[8]
Piselli P., Taborelli, M., Cimaglia, C. and Serraino, D. (2019) Decresed Incidence of Kaposi Sarcooma after Kidney Transplant in Italy and Role of mTOR-Inhibitors: 1997-2016. International Journal of Cancer, 145, 597-598. https://doi.org/10.1002/ijc.32098
[9]
Montaner, S., Sodhi, A., Molinolo, A., Bugge, T.H., Sawai, E.T., et al. (2003) Endothelial Infection with KSHV Genes in Vivo Reveals that vGPCR Initiates Kaposi’s Sarcomagenesis and Can Promote the Tumorigenic Potential of Viral Latent Genes. Cancer Cell, 3, 23-26. https://doi.org/10.1016/S1535-6108(02)00237-4
[10]
Stallone, G., Schena, A., Infante, B., Paolo, S.D., Loverre, A., Maggio G., et al. (2005) Sirolimus for Kaposi’s Sarcoma in Renal-Transplant Recipients. The New England Journal of Medicine, 352, 1317-1323. https://doi.org/10.1056/NEJMoa042831
[11]
Penn. I. (1995) Sarcomas in Organ Allograft Recipients. Transplantation, 60, 1485-1491. https://doi.org/10.1097/00007890-199560120-00020
[12]
Cahoon, E.K., Linet, M.S., Clarke, C.A., Pawlish, K.S., Engels, E.A. and Pfeiffer, R.M. (2018) Risk of Kaposi Sarcoma after Solid Organ Transplantation in the United States. International Journal of Cancer, 143, 2741-2748. https://doi.org/10.1002/ijc.31735
[13]
Harzallah, A., Ounissi, M., Hajji, M., Chargui, S., Hedri, H., Abderrahim, E., et al. (2021) Succès du traitement par paclitaxel d’une rechute viscérale d’un sarcome de kaposi après transplantation rénale. Néphrologie & Thérapeutique, 17, 132-136. https://doi.org/10.1016/j.nephro.2020.10.010
[14]
Bécuwe, C., Euvrard, S., Bosshard, S., Pouteil-Noble, C., Garnier, J.-L., Lefrançois, N., et al. (2005) Maladie de Kaposi et transplantation d’organes: 22 cas. Annales de Dermatologie et de Vénéréologie, 132, 839-843. https://doi.org/10.1016/S0151-9638(05)79501-6
[15]
Farge, D. (1993) Kaposi’s Sarcoma in Organ Transplant Recipients. The Collaborative Transplantation Research Group of Ile de France. The European Journal of Medicine, 2, 339-343.
[16]
Ducloux, D. (2017) Cancers après transplantation rénale. Traité de Néphrologie, 8, 677-682.
[17]
Penn, I. (1997) Kaposi’s Sarcoma in Transplant Recipients. Transplantation, 64, 669-673. https://doi.org/10.1097/00007890-199709150-00001
[18]
Firoozan, A., Hosseini Moghaddam, S.M., Einollahi, B., Pour-Reza-Gholi, F., Nafar, M., Basiri, A., et al. (2005) Outcome of Kaposi’s Sarcoma and Graft Following Discontinuation of Immunosuppressive Drugs in Renal Transplant Recipients. Transplantation Proceedings, 37, 3061-3064. https://doi.org/10.1016/j.transproceed.2005.07.042
[19]
Geissler, E.K., Schlitt, H.J. and Thomas, G. (2008) mTOR, Cancer and Transplantation. American Journal of Transplantation, 8, 2212-2218. https://doi.org/10.1111/j.1600-6143.2008.02391.x
[20]
Luppi, M., Barozzi, P., Rasini, V., Riva, G., Re, A., Rossi, G., et al. (2002) Severe Pancytopenia and Hemophagocytosis after HHV-8 Primary Infection in a Renal Transplant Patient Successfully Treated with Foscarnet. Transplantation, 74, 131-132. https://doi.org/10.1097/00007890-200207150-00023
[21]
Gomez, E., Aguado, S., Rodriguez, M. and Alvarez-Grande, J. (1998) Kaposi’s Sarcoma after Renal Transplantation—Disappearance after Reduction of Immunosuppression and Reappearance 7 Years Later after Start of Mycophenolate Mofetil Treatment. Nephrology Dialysis Transplantation, 13, 3279-3280. https://doi.org/10.1093/ndt/13.12.3279
